Biography

Experienced biotech executive and finance leader.

Piers qualified as a Chartered Accountant in PwC’s London office before spending almost 10 years as an investment banker, focusing on Mergers, Acquisitions and Financings, initially at Close Brothers and later in Ernst & Young’s Lead Advisory practice.

In 2000 he joined Arrow Therapeutics (sold to Astra Zeneca for $150m) before working as CFO for a number of other biotech companies in UK, France, Netherlands, and Ireland. He has led IPOs on Nasdaq (uniQure: QURE and Verona: VRNA), as well as on AIM and Euronext Paris, and has raised more than $400m in new equity, convertibles, venture debt and strategic big-pharma investments. He has also been involved in numerous licensing transactions and the sale of Quethera to Astellas for £85m.

Piers holds an MA in Law and Management Studies from Cambridge University.

"COMPASS has built an exceptional team to address the challenge of developing an effective therapeutic pathway which can bring new treatment approaches to this substantial area of unmet medical need. I feel privileged to join COMPASS on such an important journey, and have been enormously impressed by everything they have already achieved."